1. Home
  2. WAT vs NTRA Comparison

WAT vs NTRA Comparison

Compare WAT & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$378.13

Market Cap

33.5B

Sector

Industrials

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$211.21

Market Cap

29.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAT
NTRA
Founded
1958
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5B
29.1B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
WAT
NTRA
Price
$378.13
$211.21
Analyst Decision
Buy
Strong Buy
Analyst Count
17
15
Target Price
$379.19
$259.07
AVG Volume (30 Days)
1.1M
1.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
0.47
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$104.66
$18.08
Revenue Next Year
$10.40
$19.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$275.05
$131.81
52 Week High
$414.15
$256.36

Technical Indicators

Market Signals
Indicator
WAT
NTRA
Relative Strength Index (RSI) 68.11 53.32
Support Level $372.18 $186.96
Resistance Level $394.24 $220.74
Average True Range (ATR) 11.43 9.69
MACD 3.52 1.61
Stochastic Oscillator 88.12 63.40

Price Performance

Historical Comparison
WAT
NTRA

About WAT Waters Corporation

Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: